Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) and Multi-pronged Canadian Research in Epithelioid Haemangioendothelioma (PRO_CARE EHE) study

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Gastrointestinal Cancer

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Int J Cancer

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group

doi: 10.1002/ijc.70280

RECOMMENDED

Head and Neck Cancer

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT

doi: 10.1016/j.lungcan.2025.108858

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Lung, Respiratory and Thoracic Cancer

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

Lung Cancer

Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K

doi: 10.1016/j.lungcan.2025.108447

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

Central Nervous System Tumors

A Systematic Study of Molecular Diagnosis, Treatment and Prognosis in Infant-Type Hemispheric Glioma): An Individual Patient Data Meta-analysis of 164 patients

Neuro Oncol

Chavaz L, Bagchi A, Dhanda SK, Toutain F, Pfister SM, Sturm D, Pietsch T, Gielen GH, Waha A, Clarke M, Lu C, Karremann M, Benesch M, Perwein T, Nussbaumer G, Kramm C, Massimino M, Biassoni V, Vinci M, Mastronuzzi A, van Vuurden D, Veldhuijzen van Zanten SEM, Mackay A, Jones C, Jones DTW, Guerreiro Stucklin AS, Tabori U, Hawkins C, Ryall S, Morales La Madrid A, Lassaletta A, Bailey S, Hargrave D, Chiang J, El-Ayadi M, Mançano BM, Manuel Reis R, Hagel C, Gorsi H, Silvestrini N, Gilani A, Papusha L, Klimo P Jr, Zhou X, Gajjar A, Robinson GW, von Bueren AO

doi: 10.1093/neuonc/noaf264

Central Nervous System Tumors

Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study

Lancet Oncol

Gui C, Wang JZ, Patil V, Landry AP, Singh O, Castelo-Branco P, Tabori U, Aldape K, Behling F, Barnholtz-Sloan JS, Horbinski C, Tabatabai G, Ajisebutu A, Liu J, Patel Z, Yakubov R, Kaloti R, Ellenbogen Y, Wilson C, Cohen-Gadol A, Tatagiba M, Holland EC, Sloan AE, Chotai S, Chambless LB, Gao A, Makarenko S, Yip S, Nassiri F, Zadeh G, International Consortium on Meningiomas (ICOM)

doi: 10.1016/S1470-2045(25)00267-0

Gastrointestinal Cancer

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

Eur J Cancer

Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V

doi: 10.1016/j.ejca.2025.116105

Related content

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

Advancing Breast Cancer Treatment with Elacestrant

A Systematic Study of Molecular Diagnosis, Treatment and Prognosis in Infant-Type Hemispheric Glioma): An Individual Patient Data Meta-analysis of 164 patients

Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)